Resources

This infographic illustrates the research and development (R&D) process for global health technologies and highlights the challenges faced in advancing products through the R&D pipeline.

This fact sheet provides background on the Sustainable Development Goals (SDGs), the critical role of health innovation in achieving the goals, and actions the US government can take to support health R&D and the SDGs.

This fact sheet provides an overview of the findings in Measuring Global Health R&D for the Post-2015 Development Agenda, a report calling for the UN and its member states to acknowledge the importance of global health R&D by including indicators to measure progress toward it in the Sustainable Development Goals (SDGs) monitoring framework.

This brochure provides of an overview of PATH’s work in the Mekong region, with a focus on Vietnam and Myanmar. It describes PATH’s strategies in vaccines and immunization, infectious diseases, maternal and child health and nutrition, sexual and reproductive health, and noncommunicable diseases.

Lymphatic filariasis (LF), primarily caused by Wuchereria bancrofti, and onchocerciasis, caused by Onchocerca volvulus (Ov), are targeted for elimination in Africa. Integration of both elimination programs offers advantages arising from overlapping geographic endemicity; ability to share treatment programs using ivermectin; shared surveillance activities for post-elimination phases; and savings in time, money, and human labor. Integration requires improved diagnostic tools for surveillance and mapping.PATH, Standard Diagnostics, Inc. (SD), and the National Institute of Allergy and Infectious Disease (NIAID) at the National Institutes of Health are collaborating to develop a biplex rapid diagnostic test (RDT) that detects IgG4 antibodies against both the Ov16 antigen, specific for O. volvulus, and the Wb123 antigen, specific for W. bancrofti. To date, the project team has developed and transferred a proof-ofconcept onchocerciasis/LF biplex test prototype to a manufacturer; completed and readied a prototype for field testing; and developed a human monoclonal IgG4 antibody positive control for Wb123 to support test quality assurance (QA).